# OnCo record idea-lung-small-cell-platform-with-shared-controls-and-subtypes (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-lung-small-cell-platform-with-shared-controls-and-subtypes/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-lung-small-cell-platform-with-shared-controls-and-subtypes" ;
  schema:name "Run small-cell lung cancer as one platform with shared controls and subtype stratification"@en ;
  schema:description "Small-cell lung cancer has had two real advances in twenty-five years. It is probably four diseases being tested as one, in separate small trials that each need their own control group."@en ;
  schema:url <https://onco.cc/ideas/idea-lung-small-cell-platform-with-shared-controls-and-subtypes/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  onco:tag "lung-evidence" ;
  onco:related <https://onco.cc/ideas/idea-sclc-subtype-directed/>, <https://onco.cc/roadmaps/trial-modernisation-roadmap/>, <https://onco.cc/roadmaps/lung-cancer-evidence-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/limited-stage-sclc/>, <https://onco.cc/cancers/extensive-stage-sclc/> ;
  onco:sections <https://onco.cc/fronts/drug-discovery/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/terms/ihc/> ;
  onco:targets <https://onco.cc/targets/dll3/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/rb1/> ;
  onco:trials <https://onco.cc/trials/lung-map/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-undruggable-targets/>, <https://onco.cc/bottlenecks/b-trial-enrolment/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/>, <https://onco.cc/key-papers/paper-george-sclc-genomic-profiles-nature-2015/>, <https://onco.cc/key-papers/paper-ahn-dellphi-301-tarlatamab-sclc-nejm-2023/>, <https://onco.cc/key-papers/paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019/> .